Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation and reducing lung injury induced by COVID-19 pneumonia [61]; it also reduces plasmatic and pulmonary IL-6 concentration. The gene discussed is NLRP3; the disease is inflammation.